Milrinon Abcur (Milrinone)

• Milrinone acts as a selective phosphodiesterase‑3 inhibitor to increase cardiac output in critical heart conditions.
• Acute decompensated heart failure: improves contractility and reduces pulmonary congestion.
• Cardiogenic shock: provides rapid inotropic support to maintain systemic perfusion.
• Low‑output cardiac states after surgery: enhances myocardial performance and stabilises haemodynamics.

• Milrinone selectively inhibits the enzyme phosphodiesterase‑3, preventing the breakdown of cyclic adenosine monophosphate (cAMP) within cardiac myocytes and vascular smooth‑muscle cells. Elevated intracellular cAMP enhances calcium influx during systole, producing a positive inotropic effect, while simultaneously causing vasodilation through smooth‑muscle relaxation, which reduces afterload and improves overall cardiac output.

Milrinone may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Hypotension: reduction in systemic blood pressure.
• Tachyarrhythmias: increased heart rate or irregular rhythm.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Flushing: transient warmth and redness of the skin.
• Diarrhoea: loose stools in some patients.

Serious or Rare Side Effects

• Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
• Severe hypotension: marked drop in blood pressure requiring intervention.
• Myocardial ischaemia: reduced coronary blood flow leading to chest pain.
• Thrombocytopenia: low platelet count increasing bleeding risk.
• Anaphylactic reactions: rare but severe allergic responses.
• Hepatic dysfunction: abnormal liver enzyme elevations.

Milrinon Abcur requires careful clinical monitoring due to its potent cardiovascular effects.

• Blood pressure monitoring: check systolic and diastolic values frequently.
• Cardiac rhythm surveillance: continuous ECG is recommended during infusion.
• Renal function assessment: dose may need adjustment in impaired clearance.
• Contraindication in severe aortic stenosis: avoid due to risk of outflow obstruction.
• Hypersensitivity screening: discontinue if allergic reaction occurs.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Milrinon Abcur can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

• Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects may cause severe hypotension.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase milrinone plasma concentrations, raising toxicity risk.
• Concurrent vasodilators (e.g., nitroprusside): may precipitate profound hypotension.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt the desired inotropic response.
• Diuretics: electrolyte shifts can predispose to arrhythmias.
• Anticoagulants: enhanced bleeding tendency may occur.